$ACON

Gould Gregory A purchased $24K of ACON

Gould Gregory A (CFO) purchased 10,000 shares of Aclarion, Inc. (ACON) at $2.45 on 2026-08-14.

Original reporting
SEC EDGAR · Gould Gregory A
Published Aug 18, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACON
Bullish
medium confidence
Mentioned
$ACON
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACONBullishLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market purchase of 10,000 shares at $2.45/share, with post-transaction holdings of 60,000 shares.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no new operational or financial catalyst in the text.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article provides no context on prior holdings, compensation, or whether the buy was opportunistic versus planned.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for Aclarion, Inc. (ACON).

Company-level read

Ticker impact

$ACONBullishMedium confidence
Context

Aclarion CFO Gould Gregory purchased 10,000 shares of ACON at $2.45/share, totaling $24,500, disclosed via Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

Form 4 shows a direct insider purchase, but the transaction size ($24.5k) is modest and there is no accompanying guidance, deal, or operational update in the filing.

Market effects

No sector-level implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax planning, diversification, or compensation-related liquidity) and do not necessarily signal improved fundamentals.

Key entities

  • Aclarion, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Gould Gregory

    CFO who reported the open-market purchase.

  • ACON

    Aclarion common stock ticker referenced in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACONMed

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI

Aclarion (Nasdaq: ACON) said it launched a U.S. Market Access Program with PRIA Healthcare to advance reimbursement and commercial adoption of its AI platform Nociscan for chronic low back pain. PRIA will support payer engagement, prior authorization and appeals. Aclarion cited UK payer approvals from three of four major private insurers as a basis for U.S. coverage discussions.

$ACONMedAI 8/10

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion (Nasdaq: ACON) said it has agreed with the Institute of Neuro Innovation in Los Angeles to expand availability of its Nociscan platform. The INI team led by neurosurgeon Amir Vokshoor will generate real-world evidence comparing Nociscan’s lumbar disc chemical biomarker data with bone metabolic information from SPECT-CT to support treatment decisions for chronic low back pain.